For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called 'plasticity', many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well. 
Background and definition of the developmental status of cell populations in CB
Beyond the realm of successfully using cord blood (CB) as a hematopoietic stem source for the treatment of hematological malignancies, clinical use has expanded into various areas such as treatment of metabolic genetic disorders, the application in patients with immunodeficiency in correcting congenital hematological abnormalities and to induce angiogenesis. It has been shown in numerous publications that in contrast to its adult BM counterpart, the stem cell compartment in CB is less mature. This has been documented extensively for the hematopoietic system, including a higher proliferative potential in vitro and in vivo, associated with an extended life span and longer telomeres. The frequency of hematopoietic cells is higher in CB than in BM. This might be explained by the proliferation and differentiation of a number of distinct sites such as yolk sac, fetal liver, thymus, spleen and BM, indicating migration through the circulation. The biological immaturity and increased frequency of hematopoietic stem cells already suggested that CB might also be an attractive source for non-hematopoietic cells. It is meanwhile accepted that CB contains unrestricted somatic stem cells (USSCs), [1] [2] [3] [4] [5] [6] mesenchymal stroma cells (MSCs) [7] [8] [9] and endothelial colony-forming cells (ECFCs). 10 ECFC have been shown to be the only circulating cells that possess all the characteristics of an endothelial progenitor cell (EPC) and are not derived from a CD45-positive hematopoietic cell. 10 Defined by the developmental stages, term CB is a fetal, multipotent cell source. At present, there is not much scientific evidence of a true pluripotent or embryonic-like status of CB cells.
For clarity, pluripotency is defined as the regeneration of all tissues including the germline (at least in mice). This criterion has not been shown so far for CB. Some studies also reported on a presumably embryonic-like nature of CB cells. [11] [12] [13] However, the related data based on the stem cell markers OCT4 and NANOG remain questionable. OCT4 and NANOG harbor potential pitfalls for data misinterpretation due to pseudogenes and alternatively spliced variants, as well as staining of the inactive form OCT4B. [14] [15] [16] [17] Therefore, the so-called embryonic-like nature of different cell populations within CB including MNC, CD34 þ and USSC was recently analyzed by our group. 18 OCT4, NANOG and SOX2 were absent in these cell populations from CB as compared with ES cells. These results were supported by the inactive status of telomerase. 19 In addition, our group was able to show that SSEA1, SSEA3 and SSEA4 analyzed by FACS (flow cytometry analysis software) cannot be used as markers of an embryonic-like phenotype, as SSEA1 recognizes the CD15 epitope, SSEA4 cross-reacts with an adult MSC subpopulation and SSEA3 is negative if correct isotope controls are applied. Embryonic stem cell markers are, if at all, only weakly expressed in CB cells. 18, 20 Indeed, these findings should not only lead to a reconsideration of the embryonic-like nature of CB cells, but also actually confirm the non-embryonic-like nature, which is an enormous advantage for the use of CB in regenerative medicine.
At 10 weeks of gestational age OCT4 is only found in the gonad, related to the presence of gonocytes. 21, 22 No other cells were positive at this developmental stage. This occurs after the OCT4-positive primordial germ cells migrate along the midline of the body to the genital ridges. So far, no other cells during embryogenesis, except the ES cells, have been identified to express OCT4. This is not unexpected, considering the biology of OCT4 in the context of the regulation of pluripotency. Pluripotent germ cell tumors are in fact preferentially diagnosed in the gonads, both ovary and testis, in which the OCT4-positive (germ) cells migrate to and under normal conditions lose their embryonic features. 21, 22 The extragonadal pluripotent germ cell tumors are predominantly identified along the midline of the body, which is likely related to a mis-migration of embryonic germ cells. 23 The presence of pluripotent cells at other anatomical localizations can be hazardous because of the potential of generating both embryonic and extraembryonic lineages of differentiation. In other words, a strict regulation of pluripotency both temporally and spatially is required for the normal development and maintenance of the adult individual. Moreover, more than 14 000 allogeneic CB transplantations have been performed to date without any germ cell tumor formation (including teratoma).
Apparently, the ability of CB to differentiate into cells of all three germ layers does not require an embryonic-like phenotype, but reflects a composition of fetal cells organized in hierarchies that are able to design and remodel tissues and organs during fetal development.
Biology of non-hematopoietic cells in CB
MSCs in CB Mesenchymal stroma cells are defined as multipotent cells with an osteogenic, chondrogenic and adipogenic differentiation potential. In 2000, adherently growing, fibroblastlike cells were identified in CB, which revealed an immunophenotype (CD45À, CD13 þ , CD29 þ , CD73 þ , CD105 þ ) similar to BM-derived MSCs. 7 Soon thereafter, Campagnoli et al. 24 confirmed the MSC-nature of such cells from fetal blood by showing that they have the potential to differentiate to osteocytes, adipocytes and chondrocytes. This mesodermal differentiation of cord blood-derived MSC has also been confirmed by other groups (complete summary in Table 1) . 8, 9, 25, 26 In addition to this classical three-mesodermal-lineage potential of typical MSC (osteogenic, adipogenic and chondrogenic), CB-derived MSC-like cells also differentiate to cells with features of skeletal muscle. 27 Nonetheless, only about 50% of cells became positive for myosin heavy chain. 27 This raises the question whether a common progenitor gives rise to the different lineage committed cells or distinct progenitors, which are either unrelated or part of a stem cell hierarchy consisting of cells with increasingly restricted differentiation potential, similar to what has been suggested for bone marrow mesenchymal stem cells (BMMSC) by Charbord et al.
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This issue becomes more complex, because other authors have described CB-MSC with an even wider differentiation spectrum that combines different germinal layers. Goodwin Table 1 Differentiation potential of selected cell populations from cord blood in vitro and in vivo In vivo in nude rat 108 In vitro by immuno-histochemistry 3 In vitro by immuno-histochemistry, patch-clamp recordings, HPLCanalysis, RT-PCR and western blot 1, 5, 6, 109 In vitro by PCR 4 In vivo in fetal sheep model 3 
MSC
In vitro by RT-PCR, alizarin red and von Kossa-staining, ALP detection, immunohistochemistry and western blot 8, 31, [110] [111] [112] [113] In vitro by safranin-O staining, RT-PCR and immunohistochemistry 8, 31 In vitro by immunohistochemistry, RT-PCR, calcium imaging and western blot [114] [115] [116] [117] In vivo in parkinsonian rat model, ischemic rat model [118] [119] [120] [121] [122] [123] In vitro by immunohistochemistry, RT-PCR, PAS-staining, urea and albumin production, western blot and LDL uptake 31, 94, 124, 125 CD34/AC133-positive (hematopoietic progenitor) cells In vitro by RT-PCR 126 In vivo in NOD/SCID mouse model 95, 96 Not defined cells from MNC In vitro by immunohistochemistry, whole-cell patch-clamp, western blot and RT-PCR [127] [128] [129] [130] [131] In vivo in spinal cord injury and intra-brain injection in rat and NOD/SCID mouse model 73, 76, [80] [81] [82] [83] [84] [86] [87] [88] [89] [90] [91] [92] [93] [132] [133] [134] In vitro by RT-PCR, PAS-staining, ELISA and western blot 135 In vivo in NOD/SCID mouse model, hepatic injury rat model, fetal rat model [136] [137] [138] Future of cord blood for non-oncology uses G Kögler et al et al. 29 described a cell population, which can give rise to cells with features of adipocytes, osteocytes and neural cells, thus, a mesodermal/ectodermal differentiation. Generation of cells with neuronal as well as glial markers has also been reported by others (for details see Table 1 ). Unquestionably, non-hematopoietic stem cells in CB seem not to be simply MSC.
USSCs in CB
In 2004, our group described multipotent cells, which we termed USSCs, [1] [2] [3] [4] [5] to distinguish the cell from the classical MSC with regard to their differentiation potential ( Figure 1) .
Unrestricted somatic stem cells have the potential to differentiate into mesodermal cells (osteoblasts, chondroblasts, at higher ages to adipocytes) cardiomyocytes-but only in the preimmune fetal sheep model and not in porcine, into ectodermal neural cells and into endodermal hepatic cells. [1] [2] [3] [4] [5] Our group was able to confirm on the clonal level that a single cell, identified by single-cell selection, gives rise to the distinct differentiated cells of mesodermal, ectodermal and endodermal origin. 30 The chondrogenic, adipogenic, osteogenic, neural and hepatic differentiation potential of CB-derived non-hematopoietic stem cells on a clonal level has also been suggested by Lee et al. 31 after limiting dilution analyses. USSC can be triggered easily toward MSC with restricted differentiation potential, depending on culture conditions (for example, calf serum containing high amounts of corticoids).
2 This 'spontaneous' mesenchymal determination may be the explanation why several groups failed to detect a wider differentiation potential and have regarded non-hematopoietic CB-derived stem cells as early mesodermal cells or simply as MSC. Markers, which delineate such differences, are currently unknown and all immunophenotypic studies describe homogenous populations. Recently, our group was able to show that adipogenic differentiation (Figure 1) is one of the functional markers to discriminate between USSC and MSC in CB; also specific markers were identified to distinguish between these cell populations in CB. 30 These results further confirm a hierarchy in the nonhematopoietic stem cells from CB. 30 In this context, it will also be important to find out why in our studies (40-60% depending on media) 1 as well as in those of others (63 8 and 23% 9 ) non-hematopoietic stem cells were obtained only from a fraction of fresh CB units.
EPCs in CB (Critser and Yoder)
Endothelial progenitor cells have been investigated as a potential source of cells for vascular repair. First described in 1997, 32 EPCs have been characterized by many investigators based on their morphology and surface Ag expression [32] [33] [34] [35] [36] but often without detailed characterization of cellular function and lineage of origin. This has resulted in the term EPC encompassing different cell populations including cells of myeloid, lymphoid or endothelial origin 10, 37 with mixed ability to contribute to the formation of blood vessels. 10, [37] [38] [39] When either low-density MNCs or isolated CD34 þ or CD133 þ enriched cells are plated on fibronectin-coated tissue culture surfaces, distinct adherent colonies emerge after 5-9 days (Figure 2a ). These colonies are referred to as colony-forming unit-Hill (CFU-Hill) colonies. CFU-Hill progeny have been shown to express the cell surface Ags CD31, CD105, CD144, CD146, vWF and KDR (VEGF-R2), which are consistent with an endothelial cell phenotype. CFU-Hill progeny also display the ability to ingest acetylated low-density lipoprotein, a feature common not only to endothelial cells, but to macrophages as well. CFU-Hill progeny exhibit a low level of proliferative potential, express several monocytes/macrophage markers including CD14, CD45 and CD115, ingest bacteria, and display non-specific esterase activity. 10, 32, 37, 40 In addition, these colonies seem to be comprised of hematopoietic progenitor cells and T lymphocytes 10, 41 and several studies have shown that these cells arise from hematopoietic origins using several different human stem cell clonal blood disorders. 10, 42 Thus, the totality of the evidence indicates that CFU-Hill and their progeny are hematopoietic cells that never become endothelial cells in vivo, 10, 43 though these cells do have a role in promoting and modulating angiogenesis. 10, 38, 44, 45 This is an important consideration, as many studies have been conducted with CB-derived CFU-Hill isolated from CD34 þ or CD133 þ cells.
In contrast to the CFU-Hill, ECFC have been shown to be the only circulating cells that possess all the characteristics of an EPC. 43 To isolate ECFCs, CB-derived MNC or CD34 þ CD45À cells are plated on a collagen I-coated surface and form adherent colonies with a cobblestone morphology between day 7 and 14 46 ( Figure 2b ). ECFCs are rare cells found at a concentration of about 0.05-0.2 cells/ml in adult peripheral blood, and are enriched in human umbilical CB being found at a concentration of about 2-5 cells/ml. 47 ECFC progeny express the cell surface Ags CD31, CD105, CD144, CD146, vWF and KDR, and uptake acetylated low-density lipoprotein. 10, 46 In contrast to CFU-Hill, ECFC progeny do not express the hematopoietic or monocyte/macrophage cell surface Ags CD14, CD45 or CD115. 10 To further differentiate the putative EPC populations, it is necessary to evaluate their functional capabilities. An EPC should be able to give rise to endothelial progeny in a clonal manner, form endothelial tubes with lumens in vitro and form de novo vessels in vivo. 43 CFU-Hill and ECFC progenies exhibit different tube formation potential when plated on Matrigel (BD Bioscience, Mississauga, ON, Canada). Although CFU-Hill progeny incorporate into human umbilical vein endothelial cells (HUVEC) formed tubes, 38 they have not shown an ability to form tubes when plated alone. 38 However, ECFC progeny form tubes when plated alone 10 and integrate into HUVEC-formed tubes on Matrigel. 38 Although often used as a specific test of endothelial cell function, the Matrigel tube formation assay is unable to function as a specific discriminator of endothelial cell function. Matrigel induces cord formation from nonendothelial cells including fibroblasts, 48 baby murine kidney cells, 49 aortic smooth muscle cells, murine leydig cells, 50 and CD14 þ monocytes 51 seeded in Matrigel. Further, the cord structures formed in Matrigel do not contain lumens, suggesting a different mechanism of tube formation than angiogenesis or vasculogenesis. 48 The CFU-Hill and ECFC progenies have different roles in tube formation in an endothelial cell-specific angiogenesis assay. CFU-Hill progeny were unable to directly form tube-like structure, whereas ECFC progeny formed structures within 72 h when plated onto a confluent layer of fibroblast cells. 39 In addition, ECFC, but not CFU-Hill, progeny were able to incorporate directly into tubes with lumens formed by differentiated ECs. In contrast, CFUHill, but not ECFC, progeny were able to increase angiogenesis in a paracrine manner.
The CFU-Hill and ECFC progenies participate in neovascularization in a hind limb ischemia nude mouse model. 40, 52 Hur et al. 38 showed that both CFU-Hill and ECFC progenies improved perfusion and capillary density in the hind limb ischemia nude mouse model 53 compared with injection of a mature endothelial cells or media alone. Although there was no significant difference in perfusion and capillary density between CFU-Hill and ECFC treatments in this model, 38 Yoon et al. 45 showed that the injection of a mixture of CFU-Hill and ECFC progenies into a hind limb ischemia nude mouse model resulted in synergistic neovascularization compared with the injection of either cell type alone. Umbilical CB ECFC progeny, but not CFU-Hill progeny, forms de novo blood vessels when seeded into a collagen fibronectin matrix and implanted in vivo. 10 To perform this assay, ECFC progeny are seeded into a rat tail collagen fibronectin matrix in vitro, and then briefly cultured at 37 1C to permit polymerization before implantation into the flank of an immunocompromised mouse, as described by Schechner et al. 53 After 14 or 28 days, the matrices are harvested and analyzed by immunohistochemistry for human blood vessel formation. ECFCseeded matrices yielded mouse anti-human CD31-labeled endothelial lumens filled with circulating mouse RBCs. However, CFU-Hill progeny were unable to form such vessels, though the cells did survive in the implanted matrix. It is important to note that, although CFU-Hill and their progeny are of hematopoietic origin and are unable to form de novo vessels in vivo, these cell populations may still contribute to neoangiogenesis particularly through a paracrine-signaling pathway.
In other studies, ECFC progeny derived from umbilical CB formed vessels that quickly regressed when implanted alone, but were stable for 4 months when co-implanted with 10T1/2 cells, 54 and human endothelial-derived vessels can be stabilized in vivo by co-implanting human mesenchymal stem and progenitor cells. BM-derived human MSCs were shown to stabilize HUVEC-derived in vivo vessels in a collagen fibronectin matrix. 55 MSC-derived perivascular cell-stabilized vessels were shown to persist for greater than 130 days.
Application of ECFC in wound healing. One potential clinical use of ECFCs is in the treatment of patients with defective wound healing due to impaired neoangiogenesis. Shepherd et al. 56 seeded tissue-engineered human skin substitutes with keratinocytes and ECFC progeny, transplanted them onto immunocompromised mice and showed the formation of human endothelial cell vessels within the skin substitute. Umbilical CB-derived ECFC progeny yielded more human vessels in the skin substitutes than either adult blood-derived ECFC progeny or HUVECs. The skin substitutes also exhibited an ingrowth of host vessels. The host angiogenic response could be diminished by the use of rapamycin. However, the use of rapamycin did not inhibit the formation of human-derived blood vessels. The authors state that the ability of implanted endothelial cells to form a vascular network when the host's angiogenic response is inhibited suggests that this strategy could be useful in treating patients with impaired wound healing. These and other reports suggest that ECFCs represent an excellent cell source for vascular engineering strategies. Although there are no reports of the use of ECFCs in human clinical trials, the excellent results with preclinical rodent studies provide some hope for patients who suffer from poor vascular function.
Other described cell populations Beside the above described cell populations CD34 þ or CD133 þ /CD45 þ , cells of embryonic characteristics, 57 OCT4 þ VSEL 58 and MLPC (multilineage progenitor cells), 59 were described showing overlapping characteristics with the above described populations. As previously discussed, some of the cell populations have to be viewed de novo on the basis of the misinterpretation of the ES-cell markers OCT4, NANOG and the stage specific Ags SSEA1, -3 and -4.
As there are myriads of publications of the regenerative ability of CB, we will try to focus on the ones that could have therapeutic applications based on cell numbers generated as well as the functional data available in vitro and in vivo, in addition to ECFC already described in the section EPCs in CB.
Characterization of non-adherent cells from fresh and cryopreserved CB
Endothelial colony-forming cells human umbilical CB being found at a concentration of about 2-5 cells/ml fresh CB can be established from nearly each fresh CB sample. CD34 þ cells in CB have a concentration of 0.1-1% and can be enriched efficiently from fresh CB applying different selection systems. If enriched, CD34 þ cells can be easily expanded several thousand folds for hematopoietic progenitor cells. In contrast, results from clinical CD34 þ selection from thawed CB have shown that the losses range up to 50%. 60 USSC and MSC cultures were initiated from 860 fresh CB with a median generation frequency of 43%. The number of colonies ranged between 1 and 11 USSC colonies per CB growing into monolayers within 2 to 3 weeks. Once established (if colonies were observed) 23, 19, 10 and 5% reached passages 1 (20.5 ± 2.5 cumulative population doubling (CPD)), 2-6 (33 ± 3 CPD), 7-8 (35 ± 5 CPD) and 9 (37.5±7.5 CPD), respectively. These results show a high heterogeneity in the growth kinetic 30 (Figures 3a-d ). These data concerning the generation frequency for the so-called MSC were also confirmed by other groups. In contrast to fresh CB, the generation of USSC from cryopreserved and thawed CB samples was associated with difficulties as expected, because in thawed CB, aggregate formation occurs that results in cell losses. As the first experiments (n ¼ 40) with unseparated frozen CB showed that the MNC output after Ficoll isolation and erythrocyte lysis was very low and the cells did not adhere to the culture flasks, subsequent experiments were performed with volume-reduced CB units (n ¼ 120), in which the majority of erythrocytes were already depleted at the time of cryopreservation. Only one experimental condition, namely the MNC isolation with erythrocyte lysis and cultivation in the presence of Myelocult/10 À7 M dexamethasone, revealed successful generation of USSC with a generation frequency of 13%. Frequently, only one colony was detected and the outgrowth of cells was low as compared with fresh samples. These results are similar to data published previously by our group. 2 As shown in Figure 3c , USSCs have much longer telomeres compared with BMMSC.
Good manufacturing practice-conform generation and cultivation of USSC from fresh CB As generation and expansion under good manufacturing practice (GMP)-conditions is mandatory for use in clinical application, the automated cell processing system Sepax (Biosafe SA, Eysins, Switzerland) with the CS900 separation kit (Biosafe SA) was used for mononuclear cell separation from CB in a similar way as described for BM MNC. 61 For the subsequent generation of USSC colonies, 30% GMP-grade FCS, low-glucose DMEM medium/ 10 À7 M dexamethasone was used. Expansion of USSC was performed in a closed system applying cell stacks (Costar Corning, Schiphol-Rijk, The Netherlands). Results achieved so far indicate that the generation frequency and quality of generated USSC under GMP conditions are equal (43.55%) to manual generation under laboratory conditions. 62 A total of 124 CB units (mean volume 84.5 ± 15.9 ml, mean number of MNC 2.68 ± 0.94 Â 10 8 cells) were processed, resulting in USSC colony formations in 53 of the samples within 14-28 days. The closed system applied was perfectly suitable to ensure safe and easy handling of the USSC, including seeding, trypsinization and harvesting. The combination of this procedure together with the cell stack system (1, 2, 5 and 10 layers) yielded cell numbers of 1 Â 10 9 USSC obtained within four passages. These USSC products could be cryopreserved, thawed and expanded further in clinical grade quality.
Application in mesodermal tissue regeneration as bone and chondrocytes including plastic surgery Tissue engineering for bone/chondrocytes is becoming an additional alternative in the treatment of traumatic and skeletal diseases. Although at present autologous BM or BM MSC is used, in elderly patients their growth and differentiation potential is restricted. Other groups are patients with head and neck tumors. Frequently, they undergo several courses of chemotherapy and therefore healing of implants is prolonged. Here, additional MSC are helpful to accelerate the healing process, but the growth and functions of MSC generated from BM is restricted. Having alternatives beside autologous MSC from BM would be an enormous advantage for these tumor patients. Both the patient survival rate can be improved, as quality of life is enriched in appropriately selected and carefully managed individuals. All USSC and MSC described in CB were capable of differentiating along the osteogenic and chondrogenic lineage (for overview see Table 1 ). (Figure 1a ) could easily be induced by dexamethasone, ascorbic acid and b-glycerol phosphate. Osteogenic differentiation was confirmed by the expression of ALP (alkaline phosphatase), osteocalcin, osteopontin, bone sialo-protein and collagen type I detected by reverse transcriptase-PCR. Pellet culture technique was frequently employed to trigger USSC toward the chondrogenic lineage. The chondrogenic nature of differentiated cells was assessed by Alcian blue staining and by the expression of the cartilage extracellular protein type II collagen. Chondrogenesis was further confirmed by reverse transcriptase-PCR for the cartilage-specific mRNAs encoding Cart-1, collagen type II and chondroadherin. Our finding for both osteogeneic and the adipogenic differentiation potential are in agreement with many other groups as shown in Table 1 . To determine the in vivo regeneration capacity for bone, the repair of critical size bone defects with USSC-loaded calcium phosphate ceramic cylinders was shown. 1 USSCs were loaded into porous ceramic cylinders of 5 mm length before implantation into the femur critical size bone defect of athymic Harlan Nude rats. At 4 weeks after transplantation, human cells were still alive within the bone defect. Images of longitudinal and crosssections showed bony healing between the cell-loaded implant and the host bone. Bony integration was established in forms of cancellous bone as detected by Toluidine blue staining. After 12 weeks, a clear bony reconstitution was observed. Jager et al. 63 confirmed the data with a larger set of animals. The in vivo chondrogenic potential was assayed by loading USSCs into gelatin sponges, which were cultured in chondrogenic medium with supplementation of TGF-b for up to 2 weeks and then implanted s.c. into nude mice. After 3 weeks, the implanted cells showed strong chondrogenic differentiation. As USSCs also show a high production of VEGF and FGF2 and express VEGF Receptor-2 the transplantation into a bone or tissue defect might support the repair process not only by initiating mineralization but also by creating an angiogenic environment. 64 
Implication of CB for cardiovascular regenerative medicine
Nishiyama et al. 65 showed that CB cells after cultivation with murine cardiomyocytes were able to contract rhythmically and synchronously, suggesting the presence of electrical communication between the fetal cardiomyocytes and the CB. MSC-like CB-derived cardiomyocytes stained positive for cardiac troponin-I and connexin 43. Furthermore, the cardiomyocyte-specific long action potential duration (186 ± 12 ms) was recorded with a glass microelectrode from the GFP-labeled CB-MSCs. Cardiomyocytes were also observed when CB-MSCs were cocultivated with mouse cardiomyocytes separated by a collagen membrane. Cell fusion, therefore, was not a major cause for the development of cardiomyocytic cells from the CB cells. Approximately, half of the CB-derived cells were successfully differentiated into cardiomyocytes in vitro. This was the first evidence of in vitro differentiation of CB cells toward cardiomyocytes. 65 In vivo animal models Differentiation of CB cells into human cardiomyocytes was first described by our group in 2004 1 by applying the preimmune fetal sheep model. The development of USSC into human cardiomyocytes in this model was analyzed 8 months after transplantation by positive staining with the human-specific anti-HSP27 Ab in both atria, both ventricles and the septum of the heart of in utero USSCtransplanted sheep. Double labeling showed that the USSC also stained positive for the anti-ryanodine receptor, antimyosin heavy chain and anti dystrophin. In this study, engraftment of USSC in the Purkinje fiber system was also detected. As the preimmune model was a developmental model, following studies in porcine addressed the question whether USSC can engraft in other more clinically relevant conditions like post infarction.
Kim et al. 66 showed in a chronic porcine model of myocardial infarction that transplanted USSC survived 1 month after intra-myocardial transplantation and were able to adopt cardiac phenotypes accompanied by improvement of myocardial function.
In collaboration with A Ruhparwar and the department of Thoracic and Cardiovascular Surgery in Hannover (Hannover Medical School, Germany) we were able to show in a porcine model of acute myocardial infarction that after 8 weeks no USSCs were detectable in the infarct area as shown by FISH (fluorescence in situ hybridization) and immunohistology. 67 Although no human cells were detectable 2 months after transplantation, the USSC preserved the recipient myocardium and prevented scar formation after acute ischemia. This was associated with a significant improvement of left ventricular ejection fraction and it prevented left ventricular dilation. 67 We were not able to confirm USSC graft survival and USSC differentiation toward cardiomyocytes. However, with 10 8 USSC used for engraftment in the study by Kim et al., the cell number exceeded ours significantly (1.2 Â 10 7 ). In addition, the observation period in the paper by Kim et al. 66 was 1 month, whereas it was 2 months in our study and cells were injected 1 month after cardial infarction or directly thereafter, respectively. With regard to these results, there are many potential explanations for the observed functional recovery and prevention of scar formation: the induction of cytokines can lead to the de novo formation of myocardium or the preservation of the recipient myocardium by paracrine effects. USSC can release a variety of cytokines as VEGF, FGF-2, SDF, SCF, HGF and, therefore, may accelerate regeneration. 2 In both studies, no side effects were observed; however, our experience indicates that high cell numbers are needed to prevent scar formation. Similar data were obtained by Chang et al.
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Other authors 69 have described that CD133 þ cells (1-2 Â 10 6 ) from CB enhance function and repair in a model of extensive myocardial infarction in athymic nude rats, confirming that the cells improve the left ventricular function by self-repair by autologous myofibroblasts that prevent scar thinning and dyskinesis instead of differentiation of the human cells toward cardiomyocytes. 69 Again, the use of off-the-shelf CB populations to repair the myocardium might be of importance to elderly people whose functional stem cells are limited.
Future of cord blood for non-oncology uses G Kögler et al
On the basis of endothelial cells enriched from CB and other cell populations producing angiogenic factors (discussed above), peripheral arterial disease of the lower extremities in people aged 65 years and older is one of the indications where 'off the shelf' CB cells could improve the clinical situation. Our institutional experience here of separating MNC from BM for patients with peripheral arterial disease as a routine approach 61, 70 has shown that frequently the number of cells harvested together with the amount and quality of CFU-F is low in patients over 65 years and very low if they are 80 years or older. For both ECFC-and MSC/MSC-like cells, several mechanisms of angiogenesis and vasculogenesis after injury in animals have been documented.
Neural differentiation/neural diseases (Trapp)
Different cellular transplantation strategies have shown some efficacy in treating different types of injuries of the central and peripheral nervous system in animal models. [71] [72] [73] Various kinds of stem cells, that is, embryonic, fetal and adult stem cells are under investigation for cellbased therapies of neurological disorders. Although embryonic and fetal stem cells may have the broadest differentiation potential, 74 their use raises serious biological, ethical and legal questions limiting a widespread clinical use of these cells at present. Moreover, allogeneic transplantation of embryonic stem cells was shown to produce highly malignant teratocarcinomas at the site of implantation in mice in a stroke model. 75 Faced with these difficulties, investigators identified and evaluated alternative stem cell sources for therapeutic use. During the past decade, human umbilical CB has created great interest as a novel valuable source for neural stem cells, which possess several unique characteristics. Several studies including our own (Figure 1c ) have shown how subsets of CB cells differentiate under defined conditions into neurons, astrocytes and microglia. Moreover, it has been reported that CB stem cells secrete trophic factors that initiate and maintain the process of repair. [76] [77] [78] [79] Most animal studies using CB-derived stem cells for the treatment of neurological disorders were performed using models for cerebral ischemia, reflecting the importance of stroke research, as cerebrovascular diseases remain the third leading cause of death in the European Union and in the United States. In 2001, Chen et al. 76 were the first to show that the infusion of CB stem cells into rats that had been stroke-induced by occlusion of the middle cerebral artery was able reduce behavioral deficits associated with this injury model. Meanwhile, other studies in different animal models of stroke have clearly shown that infusion as well as intracerebral transplantation of CB-derived stem cells display beneficial effects. 73, 76, [80] [81] [82] [83] [84] [85] The mechanisms underlying the observed beneficial effects of these therapies have not yet been elucidated. The most straightforward idea is that stem cells differentiate into mature cell types and simply replace the lost tissue. However, there is increasing evidence that transplanted cells may secrete neurotrophic or neuroprotective factors that can counteract degeneration or promote regeneration. 79 Moreover, it is possible that an inflammatory modulating action of stem cells from CB reduces stroke-initiated damage. 86 In a recent study applying CB stem cells in a rodent stroke model, 5 it was shown that USSCs isolated from human CB are strongly attracted by hepatocyte growth factor (HGF) that is secreted by ischemia-damaged brain tissue and by apoptotic neurons in vitro and in vivo. Necrotic neurons do not secret hepatocyte growth factor and have no potential to initiate migration of USSC. In all paradigms used in this study the secretion of HGF by neural target tissue and the expression of the HGF receptor c-MET in USSC directly correlated to migrational potency of USSC strongly, indicating that the HGF/c-MET axis is the driving force for USSC migration toward neuronal injury. As migration of USSC toward apoptotic neurons can be blocked completely by a neutralizing Ab that inhibits the bioactivity of HGF, it can be concluded that HGF is necessary to attract USSC toward neuronal damage. These findings shed important light on the role of the HGF/c-MET axis in neural regeneration. HGF is a multifunctional cytokine that was originally characterized as a mitogen for hepatocytes. Meanwhile, HGF is known to evoke a multitude of cellular responses in various cell types and organs. The function of HGF is mediated through its receptor c-MET. Binding of the ligand leads to autophosphorylation of multiple tyrosine residues located in the cytoplasmic domain of c-MET-activating cellular cascades that lead to angiogenesis, cellular motility, growth, invasion, morphological differentiation, embryonic development and tissue regeneration. Moreover, a deregulated activation of c-MET has been shown to be crucial for the acquisition of tumorigenic properties, and the involvement of c-MET in different human tumors has been established and described by others. In addition to all the functions that are already attributed to the HGF/c-MET axis, the results of this study show that the interplay of HGF and its receptor is crucial for the cross talk between neuronal injury and CB-derived stem cells. Together with their proven neural differentiation potential, 1 the prominent tropism for apoptotic neurons makes USSC a serious candidate for cell replacement therapies of different neurological diseases. In a number of neurological diseases, proapoptotic signal transduction is activated and therefore it is well possible that USSCs are attracted by brain lesions resulting from those diseases. Moreover, USSCs can potentially be used as vehicles, as their tropism for neuronal injury might deliver neuroprotective factors in a targeted way toward a lesion.
Owing to their broad neural differentiation potency, CBderived stem cells were also investigated concerning their regenerative potential in animal models of amyotrophic lateral sclerosis, Parkinson's disease, cerebral palsy, traumatic brain injury and spinal cord injury. [87] [88] [89] [90] [91] [92] [93] In most studies, infusion of CB stem cells resulted in observable behavioral improvement compared with control animals. In a model of traumatic brain injury, for example, Lu et al. 90 showed that intravenous infusion of CB stem cells resulted in a migration of stem cells toward the brain injury. Moreover, stem cells expressed neural markers, and a significant reduction of the lesion compared with controls was observed.
Future of cord blood for non-oncology uses G Kögler et al
Although most studies using CB stem cells for the treatment of neurological disorders in animal models are very promising, several questions as the route of administration, the amount of cells and the mode of action have to be addressed before stem cells from CB can be brought into the clinical arena as a therapeutic strategy to treat neurological disorders.
Endodermal differentiation
Organ transplantation provides a definitive cure for pancreas or liver diseases. Although technical improvements are made continuously, procedures employed still carry considerable risks and limitations. More importantly, the limited availability of transplantable organs remains a growing impediment to this form of therapy. In comparison, stem cell therapies might be a minimally invasive procedure and could offer a potentially unlimited source of cells for tissue replacement.
To evaluate the potential of USSC to differentiate into liver cells, in utero transplantation into fetal sheep was employed and livers of the sheep were taken 14 months post USSC transplantation. In total, 21.1±3.2% of total liver cells were stained positive by the Ab that specifically recognizes human hepatocytes. Some of the liver cells showed a very strong pattern of albumin staining. A western blot showed a specific human albumin band and thus the functional production of this human protein in vivo in serum of the sheep obtained 17 months after transplantation of the USSC in utero. No fusion to host cells occurred. 1 As the in vivo results were very encouraging, our group examined whether it was possible to trigger USSC in vitro into the endodermal differentiation pathway applying protocols described for both embryonal as well as adult stem cells. Primers were designed with the strategy to define stages of endodermal development on the basis of the embryonic cell development from mouse and human. The following markers were established: GATA 4, HNF-1, HNF3b and HNF 4a to define the embryonic and visceral (extra-embryonic) endoderm, a common precursor phenotype for both liver/exocrine pancreas development. To further assess differentiation into liver cells, a-1 antitrypsin, a-fetoprotein, albumin, HGF, Cyp2B6, Cyp3A4, Gys2 and PDX-1, PAX4, ISL-1, NKx6.1, NeuroD, and insulin to determine differentiation into the pancreatic development as well as epithelial markers as CK8, CK18, CK19 were analyzed by reverse transcriptase-PCR and on the protein level. Several markers were already present in native USSC: HGF, Cyp1A1, CD26, CK8, CK18, a-1 antitrypsin. In vitro differentiation applying different culture conditions showed that USSC never expressed Neuro D, HNF1, HNF3b, PDX-1, PAX4, insulin and a-fetoprotein, but do express Isl-1, glycogensynthase 2, albumin, gata 4 and Cyp3A4 (weak) and Gly2 as well as Isl-1. Although an endodermal precursor phenotype could be generated, the production and secretion of functional active liver enzymes as urea and the cytochrome Cyp3A4 was very weak in comparison with adult human liver or the HepG2 cell line. 3, 4 Endodermal differentiation in vitro applying MSC from CB was also confirmed by Lee et al. 94 applying a two-step protocol with hepatocyte growth factor and oncostatin M resulting in in vitro functions of liver cells as Phenobarbital-inducible cytochrome p450 activity. Besides USSC and MSC, there are no further substantial data available concerning in vitro endodermal hepatic differentiation. Table 1 presents the summary on in vivo data. Ishikawa et al. 95 showed that CD34 þ CD45 þ cells were able to give rise to hepatocytes in mice. The generation of amylase-producing pancreatic acinar cells in NOD-SCID/ B2m null mice was published by Minamiguchi. 96 No publication so far documented a generation of pancreatic insulin-producing b cells, neither based on functional pathways in vitro nor in vivo.
As there are encouraging data available with regards to an endodermal liver cell phenotype (Figure 1d) , one clinical application today could be the regeneration of liver after portal vein embolization in patients with large liver tumors. Preliminarily data applying USSC in a sheep model focusing on this approach look promising (personal communication, A Ruhparwar, Medical Center, University of Heidelberg).
At present, CD133 þ cells from autologous BM (200-400 ml) in combination with portal vein embolization are used to substantially increase hepatic regeneration in patients with large hepatic malignancies. 97 The mechanism behind-fusion vs actual regeneration has not been described so far.
Other clinical protocols focus on the use of autologous CB to treat patients with type 1 diabetes. 98 The aim of the study is to restore the proper immune regulation. Even if this kind of blood transfusion has an influence on the homeostasis of T cells, it does not regenerate the destroyed insulin-producing b cells. All children treated are still dependent on insulin. Finally, multiple approaches describing the modulation or suppression of the autoimmune response by addition of MSC are documented.
Hematopoiesis-supporting activity of USSCs and MSC from CB
Our group has studied cytokine production and in vitro hematopoiesis-supporting stromal activity of USSC in vitro in comparison with BM-derived MSC.
2 USSC constitutively produced many cytokines including SCF, LIF, TGF1b, M-CSF, GM-CSF, VEGF, IL-1b, IL-6, IL-8, IL-11, IL-12, IL-15, SDF-1a and HGF. When USSC were stimulated with IL-1b, G-CSF was released. Production of SCF and LIF was significantly higher in USSC compared with BMMSC. To determine the hematopoiesis-supporting stromal activity of USSC compared with BMMSC, CB CD34 þ cells were expanded in co-cultures. At 1, 2, 3 and 4 weeks, co-cultivation of CD34 þ cells on the USSC layer resulted in a 14-, 110-, 151-and 183.6-fold amplification of total cells and in a 30-, 101-, 64-and 29-fold amplification of CFC, respectively. In summary, USSC produce significant amounts of hematopoiesis-supporting cytokines and are superior to BMMSC in supporting the expansion of CD34 þ cells from CB. USSC are therefore a suitable candidate for stroma-driven ex vivo expansion of hematopoietic CB cells for short-term reconstitution.
In vivo data of Chan et al. 99 have shown that USSC induced a significant enhancement of CD34 þ cell homing to both BM and spleen. In the publication of Huang et al., CB-MSC were used for the ex vivo expansion of CB progenitors and resulted in a fast recovery after transplantation in NOD-SCID mice.
CB in regenerative medicine: do we need immune suppression?
As summarized in a review by Riordan et al., 100 the widespread clinical entry of CB for non-hematopoietic tissue regeneration will also depend on, whether a patient needs to be immunosuppressed or not. Riordan 100 discussed that in a condition as Krabbe disease, in which patients rarely survive beyond the age of 2 years, CB transplant was shown to induce 100% survival, thus justifying the need for myeloablation. For conditions such as induction of angiogenesis in patients, in which the population already suffers from major co-morbidities and the potential benefit of CB is only speculative, the justification for myeloablation rapidly diminishes. The authors also reviewed the reasons and rationales why in some situations (for example with certain cell populations from CB) no or minimal immune suppression of the recipient is required.
Some of the preclinical data with CB described above were also performed without immune suppression. Currently, there are ongoing clinical trials in phase I-III using 'universal donor' MSC in non-conditioned recipients for treatment of Cohn's disease and myocardial infarction (for review see Riordan et al.
100
). The fact that regulatory agencies allowed universal donor MSC supports this idea of an allogeneic setting at least for the USSC/MSC populations from CB. There are at present three reports of non-conditioned recipients treated with allogeneic BM. The first described four patients with Buerger's disease who received 4/6 HLA-matched CB locally in the area of limb ischemia. 101 A second report was published on allogeneic MSC from CB administered in a patient with spinal cord injury at the site of injury. 102 The third report described two patients with non-healing wounds who were treated with autologous fibrin glue containing allogeneic CB isolated CD34 þ cells. 103 Immunological properties of USSC As described by our group in cooperation with A Dickinson (Newcastle), USSC are conditionally immunosuppressive, and IFNg and TNFa constitute a switch that regulates their immunological properties. 104 They either suppress T-cell responses in the presence of both cytokines or in their absence block DC differentiation and function. These activities may contribute to an adaptation of the immune system especially at sites of tissue damage. Therapeutically, they may help to protect USSC from immune rejection. Recently, van den Berk et al. 105 have shown that USSC differ from BMMSC with regard to the Toll-like receptor ligands.
Perspectives
Expanding the use of CB to patients for regenerative applications would be an enormous practical advancement in stem cell therapeutics. As discussed by Riordan et al., 100 by overcoming allogeneic barriers in regenerative medicine, the fundamental limitations of autologous cell therapy may result in effective 'off the shelf' standardized cellular products for regenerative therapeutics.
This requires understanding of the unique immunology of each of the presented cell populations, choosing indications in which application of cells is safe, and combining cell populations or amplifying cellular effects by combination with various drugs.
As stated by Regenberg et al., 106 for neurological conditions, very qualified preclinical animal models together with a state of the art monitoring as shown by Weber et al. 107 will be needed in advance of the first inhuman clinical trials. The recent guidelines for the 'Clinical Translation of stem cells' by the ISSCR (http://www. isscr.org) seem to be highly recommended for any stem cell sources applied.
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